Clinical Trials in Washington D.C., District of Columbia
22 recruiting
Showing 1–20 of 126 trials
Recruiting
Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled340 locationsNCT03191149
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled576 locationsNCT03866382
Recruiting
Phase 3
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled192 locationsNCT07195695
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 1Phase 2
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Advanced Solid Tumor
Synthekine364 enrolled27 locationsNCT05098132
Recruiting
Phase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NSCLC
Regeneron Pharmaceuticals231 enrolled40 locationsNCT04077099
Recruiting
Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled316 locationsNCT06096844
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1149 locationsNCT04267848
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Merck Sharp & Dohme LLC1,065 enrolled47 locationsNCT04165798
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled67 locationsNCT06863272
Recruiting
Phase 1Phase 2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled250 locationsNCT06841354
Recruiting
Phase 2
Circulating Tumor DNA
ER+ Breast Cancer
Yale University50 enrolled7 locationsNCT06923527
Recruiting
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.538 enrolled144 locationsNCT06538038
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Georgetown University18 enrolled4 locationsNCT04499053